Catalent, Inc.
14 Schoolhouse Road
Somerset, NJ 08873
United States
732 537 6200
https://www.catalent.com
版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 18,000
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Alessandro Maselli | President, CEO & Director | 1.08M | 無 | 1972 |
| Dr. Aristippos Gennadios Ph.D. | Group President of Pharma & Consumer Health Segment | 799.26k | 無 | 1966 |
| Mr. Ricky Hopson | President, Division Head for BioProduct Delivery & Chief of Staff | 622.12k | 無 | 1977 |
| Mr. John J. Greisch M.B.A. | Executive Chairman of the Board | 125k | 無 | 1955 |
| Mr. Matti M. Masanovich | Senior VP & CFO | 無 | 無 | 1972 |
| Mr. Michael J. Hatzfeld Jr. | VP & Chief Accounting Officer | 無 | 無 | 1973 |
| Mr. Charles Lickfold | Senior VP & Chief Information Officer | 無 | 無 | 1974 |
| Mr. Paul Surdez | Vice President of Investor Relations | 無 | 無 | 無 |
| Mr. Joseph A. Ferraro J.D. | Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary | 無 | 無 | 1978 |
| Mr. Michael J. Grippo | Senior Vice President of Strategy & Corporate Development | 無 | 無 | 1969 |
描述
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.
公司管治
截至 2024年5月1日 止，Catalent, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：10；董事會：8；股東權利：6；現金賠償：7。
